Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for korean women with breast cancer: Retrospective cohort study of the korean breast cancer society database

Clinical Therapeutics

Volumn 32, Issue 6, 2010, Pages 1122-1138

  Yang, Jae Jeong ^a,b   Park, Sue K ^a,b   Cho, Lisa Y ^a,b   Han, Wonshik ^a,b   Park, Boyoung ^a,b   Kim, Hyeongsu ^c   Lee, Kun Sei ^c   Hahn, Seo Kyung ^a   Cho, Sung il ^b   Ahn, Sei Hyun ^d   Noh, Dong Young ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Konkuk University School of Medicine   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

Author keywords

Breast cancer; Cost effectiveness; Estrogen receptor; Progesterone receptor; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; COST EFFECTIVENESS ANALYSIS; DISTANT METASTASIS; DRUG EFFICACY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POSTOPERATIVE CARE; RETREATMENT; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SOUTH KOREA;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; KOREA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REGISTRIES; RETROSPECTIVE STUDIES; TAMOXIFEN;

EID: 77954633080     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.05.013     Document Type: Article

References (35)

1. Ferlay J, Bray F, Pisani P, Parkin DM GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Database no. 5, version 2.0 2001, International Agency for Research on Cancer, Lyon, France.
2. Choi Y, Kim YJ, Shin HR, et al. Long-term prediction of female breast cancer mortality in Korea. Asian Pac J Cancer Prev. 2005, 6:16-21.
3. National Cancer Information Center Accessed November 1, 2009. http://www.cancer.go.kr/cms/statics/incidence/index.html.
4. Shin HR, Jung KW, Won YJ, et al. 2002 Annual report of the Korea central cancer registry: Based on registered data from 139 hospitals. Cancer Res Treat. 2004, 36:103-114.
5. Ko SS Chronological changing patterns of clinical characteristics of Korean breast cancer patients during 10 years (1996-2006) using nationwide breast cancer registration on-line program: Biannual update. J Surg Oncol. 2008, 98:318-323. Korean Breast Cancer Society.
6. Breast Cancer Surveillance Consortium: Working together to advance breast cancer research National Cancer Institute, Accessed December 12, 2008. http://breastscreening.cancer.gov/data/variables/freq_tables_pct.html#menopause.
7. Survival analysis of Korean breast cancer patients diagnosed between 1993 and 2002 in Korea: A nationwide study of the cancer registry. J Breast Cancer. 2006, 9:214-229. Korean Breast Cancer Society.
8. Dunnwald LK, Rossing MA, Li CI Hormone receptor status, tumor characteristics, and prognosis: A prospective cohort of breast cancer patients. Breast Cancer Res. 2007, 9:R6.
9. Bonneterre J, Thürlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000, 18:3748-3757.
10. National Institutes of Health Consensus Development Conference statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 2001, 5-15. National Institutes of Health Consensus Development Panel.
11. Yun YH, Park SM, Noh DY, et al. Trends in breast cancer treatment in Korea and impact of compliance with consensus recommendations on survival. Breast Cancer Res Treat. 2007, 106:245-253.
12. Ahn SH, Yoo KY Chronological changes of clinical characteristics in 31,115 new breast cancer patients among Koreans during 1996-2004. Breast Cancer Res Treat. 2006, 99:209-214. Korean Breast Cancer Society.
13. AJCC Cancer Staging Manual 1997, Lippincott-Raven, Philadelphia, Pa. 5th ed. I.D. Fleming, J.S. Cooper, D.E. Henson (Eds.).
14. Ahn SH, Son BH, Kim SW, et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: Nationwide survival data in Korea-a report from the Korean Breast Cancer Society. J Clin Oncol. 2007, 25:2360-2368. Korean Breast Cancer Society.
15. Sobin LH, Fleming ID TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997, 80:1803-1804.
16. The National Assembly of the Republic of Korea Accessed May 6, 2010. http://likms.assembly.go.kr/law/jsp/Law.jsp?WORK_TYPE=LAW_BON&LAW_ID=A1836&PROM_NO=09932&PROM_DT=20100118&HanChk=Y.
17. Korean Breast Cancer Society Accessed October 20, 2009. http://www.kbcs.or.kr.
18. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet. 1998, 351:1451-1467. Early Breast Cancer Trialists' Collaborative Group.
19. National Health Insurance Corporation Accessed December 2, 2009. http://www.nhic.or.kr/portal/site/main/menuitem.b49c0a238bc4dd38b31148b4062310a0.
20. Korean Statistical Information Service Accessed December 1, 2008. http://kosis.kr/nsp/wnsearch/totalSearch.jsp.
21. Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007, 99:283-290.
22. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group.
23. Khoshnoud MR, Fornander T, Johansson H, Rutqvist LE Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen. Breast Cancer Res Treat. 2008, 107:71-78.
24. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003, 361:296-300.
25. Delea TE, El-Ouagari K, Karnon J, Sofrygin O Costeffectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat. 2008, 108:375-387.
26. Jordan VC Estrogen receptormediated direct and indirect antitumor effects of tamoxifen. J Natl Cancer Inst. 1990, 82:1662-1663.
27. Lee SG, Jee YG, Chung HC, et al. Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: Docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC). Breast Cancer Res Treat. 2009, 114:589-595.
28. Noe LL, Becker RV, Gradishar WJ, et al. The cost effectiveness of tamoxifen in the prevention of breast cancer. Am J Manag Care. 1999, 5(Suppl 6):S389-S406.
29. McCabe C, Claxton K, Culyer AJ The NICE cost-effectiveness threshold: What it is and what that means. PharmacoEconomics. 2008, 26:733-744.
30. Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge?. Value Health. 2004, 7:518-528.
31. Kievit W, Bolster MJ, van der Wilt GJ, et al. Cost-effectiveness of new guidelines for adjuvant systemic therapy for patients with primary breast cancer. Ann Oncol. 2005, 16:1874-1881.
32. Choosing interventions that are cost effective (WHO-CHOICE) World Health Organization, Accessed December 18, 2008. http://www.who.int/choice/costs/CER_thresholds/en/index.html.
33. Economic Statistics System The Bank of Korea, Accessed May 6, 2010. http://ecos.bok.or.kr.
34. Papaioannou A, Kennedy CC, Dolovich L, et al. Patient adherence to osteoporosis medications: Problems, consequences and management strategies. Drugs Aging. 2007, 24:37-55.
35. Barron TI, Connolly R, Bennett K, et al. Early discontinuation of tamoxifen: A lesson for oncologists. Cancer. 2007, 109:832-839.